POINT Biopharma Global, Inc. Financials

Market Capitalization $None as of Jan. 11, 2021

Valuations Metrics as of May. 5, 2024

Trailing PE	21.25
Forward PE	20.21
Price to Sales TTM	€3.03
Price to Book MRQ	€3.72
Enterprise to Revenue	3.54
Enterprise to EBITDA	16.01

Financial Reports as of Mar. 31, 2024

Financials

Fiscal Year Ends	2023-12-31
Most Recent Quarter	2024-03-31
Profit Margin	15.30%
Operating Margin	19.94%
Return on Assets TTM	7.36%
Return on Equity TTM	20.46%

Income Statement

Revenue TTM	€3,828,071,804
Revenue per Share TTM	€24.76
Quarterly Revenue Growth	-1.10%
Gross Profit TTM	€1,519,200,000
EBITDA	€849,700,000
Net Income to Common TTM	€587,243,504
Diluted EPS TTM	€3.51
Quarterly Earnings Growth YoY	2.80%

Balance Sheet

Total Cash MRQ	€102,035,775
Total Cash per Share MRQ	€0.66
Total Debt MRQ	€
Total Debt to Equity MRQ	66.31
Current Ratio MRQ	1.90
Book Value per Share MRQ	€20.04

Cash Flow

Operating Cash Flow TTM	€578,171,550
Levered Free Cash Flow TTM	€390,349,976

PNT Stock Info as of May. 5, 2024

Stock Statistics

Shares Outstanding	166,024,992
Float Shares	165,131,411
Avg 10 Volume	43
Avg 30 Volume	None
Shares Short	None
Short Ratio
Short % of Shares	%
% Held by Insiders	0.61%
% Held by Institutions	97.84%

Stock Price Summary

Beta	1.23
Fifty Two Week Low	€51.40
Fifty Two Week High	€79.22
Fifty Two Week Change	27.66%
Day 50 MA	€73.94
Day 200 MA	€65.05

Dividends and Splits

Forward Annual Dividend Rate	€0.92
Forward Annual Dividend Yield	1.25%
Trailing Annual Dividend Rate	€0.90
Trailing Annual Dividend Yield	1.22%
Payout Ratio	23.61%
Dividend Date
Ex Dividend Date	2024-04-18
Last Split Factor
Last Split Date